ALBO News and Press, Albireo Pharma Inc. From 01/29/20

BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its commo...

Albireo Pharma (NASDAQ: ALBO ) is down 3% in light trading after hours after proposing a public offering of common stock. More news on: Albireo Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with...

—  Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 — —  To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020  — BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-...

BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille Awareness Day on January 24, 2020, acknowledging pediatric hepatol...

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Jefferies 2019 Londo...

Albireo Pharma, Inc. (ALBO) Q3 2019 Earnings Conference Call November 6, 2019 10:00 AM ET Company Participants Paul Arndt - LifeScience Advisors Ron Cooper - President and Chief Executive Officer Simon Harford - Chief Financial Officer Patrick Horn - Chief Medical Officer Pam...

Image source: The Motley Fool. Albireo Pharma, Inc.   (NASDAQ: ALBO) Q3 2019 Earnings Call Nov 6, 2019 , 10:00 a.m. ET Operator Continue reading

Albireo Pharma (NASDAQ: ALBO ): Q3 GAAP EPS of -$1.73 misses by $0.17 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

—  Phase 3 PFIC trial randomization more than three-quarters complete. — — Topline results expected mid-2020. — — Pivotal trial in biliary atresia expected to be initiated in 2020.   — — Management to host conference ca...